FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Ke C, Xiao C, Li J, Wu X, et al. Hepatology 2025;81:181-197.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Ke C, Xiao C, Li J, Wu X, et al. FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Hepatology 2025;81:181-197.
PMID: 37874228